The history of the erectile dysfunction drug presents a complex picture for investors. While the initial launch generated substantial returns, the expiration of its patent opened the floodgates to cheaper alternatives, https://socialeweb.com/story7129587/the-copyright-and-big-pharma-a-risky-opportunity